Graceway Pharmaceuticals, LLC Reports Study in British Journal of Dermatology: Patients Treated with ALDARA Experienced Higher Levels of Histological and Sustained Clearance for Actinic Keratosis (AK) than Patients in two Other Common AK Treatments

BRISTOL, Tenn.--(BUSINESS WIRE)--Graceway Pharmaceuticals, LLC today announced the results from a study comparing 3 different treatments for actinic keratosis, a skin condition that can become cancerous if left untreated. This study evaluated three common treatment options: imiquimod 5% cream (ALDARA), topical 5-fluorouracil (5-FU), and cryotherapy. The results of this study demonstrated that patients treated with ALDARA experienced the highest level of histological (biopsy confirmed) clearance among patients in the three treatment arms. In addition, 12 months after treatment, significantly more patients remained disease free with ALDARA than after treatment with cryotherapy or 5-FU. The design and detailed results of this randomized clinical study and additional scientific findings are described below.

Back to news